Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

958
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
958
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

883
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
883
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

957
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
957
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

8.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline serum metabolites predict fractures in individuals who were Black and had type 2 diabetes.

Frontiers in endocrinology·2026
Same author

The periosteum as an endocrine organ: historical foundations and new insights.

Open biology·2026
Same author

Bone as an endocrine regulator of lipid and energy metabolism.

Reviews in endocrine & metabolic disorders·2026
Same author

11β-Hydroxysteroid dehydrogenase type 1 deficiency causes sexual dimorphism in body composition and bone mass in response to caloric restriction.

JBMR plus·2026
Same author

Neuroendocrine and neural control of bone mass in health and disease.

The Journal of clinical investigation·2026
Same author

Intact mTOR signaling in gastric X/A-like cells is required for bone homeostasis.

Frontiers in endocrinology·2026
Same journal

Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.

The New England journal of medicine·2026
Same journal

Opportunities to Combat the Chronic Pain-Opioid Use Disorder Syndemic.

The New England journal of medicine·2026
Same journal

The Invisible Load of Cognitive Symptoms.

The New England journal of medicine·2026
Same journal

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026
Same journal

Cat Scratch Disease.

The New England journal of medicine·2026
Same journal

Declarations of Independence - Physicians and the U.S. Body Politic, 1776-2026.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

10.1K

GLP-1 Receptor Agonists.

Clifford J Rosen1,2, Julie R Ingelfinger

  • 1Tufts University School of Medicine, Boston.

The New England Journal of Medicine
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 (GLP-1) receptor agonists effectively manage type 2 diabetes and obesity by improving insulin release and promoting weight loss. These treatments also offer significant cardiovascular and renal protective benefits.

More Related Videos

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

16.3K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K

Related Experiment Videos

Last Updated: Apr 4, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

10.1K
Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

16.3K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues used for type 2 diabetes and obesity.
  • They influence glucose-mediated insulin release, gastric emptying, glucagon secretion, and satiety.

Purpose of the Study:

  • To review the multifaceted mechanisms and clinical benefits of GLP-1 receptor agonists.
  • To highlight their impact beyond glycemic control and weight loss, including cardiovascular and renal protection.

Main Methods:

  • Review of large-scale randomized, controlled trials.
  • Analysis of pharmacological actions and clinical outcomes.

Main Results:

  • GLP-1 receptor agonists reduce cardiovascular risk and slow renal failure progression in high-risk individuals and those with type 2 diabetes.
  • Primary side effects are gastrointestinal, with potential loss of muscle and bone mass.

Conclusions:

  • GLP-1 receptor agonists demonstrate significant benefits for glycemic control, weight management, cardiovascular health, and renal function.
  • Further research is needed on long-term adherence, weight regain, and the implications of muscle and bone mass loss.